Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The largest sun of 2026 rises today as Earth draws closest to our parent star - 2Sought-After Extravagance Ocean side Objections for a Lovely Escape
- 3Tech Patterns 2023: 12 Advancements to Keep an eye Out For
- 4The Most Enrapturing Authentic Milestones to Visit
- 5BioMarin to acquire Amicus Therapeutics for $4.8 billion in rare disease bet
- Worldwide Objections Ideal For A Golf Outing
- Nepal’s youngest premier sworn in after releasing new rap song about unity
- Cruising Solo All over the Planet: An Excursion of Self-Disclosure
- Ukraine to get up to 100 French-made Rafale fighter jets
- Crypto Investor’s Family Tied Up and Beaten by Armed Gangs in Their Home
- German foreign minister heads to China to talk rare-earth exports
- Misjudged Objections For Solo Voyagers
- Lilly, Novo lock horns in India's obesity drug race
- Study finds humans were making fire 400,000 years ago, far earlier than once thought
